Business Wire

SPLIO

Share
Splio Acquires Tinyclues to Become the European Leader in AI-powered CRM

Splio, CRM expert and developer of the SaaS Individuation® marketing platform, is proud to announce the acquisition of Tinyclues, the specialist in SaaS predictive marketing based on deep learning AI. This acquisition fulfills a shared ambition to enable brands to easily orchestrate large-scale, hyper-personalized marketing plans.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230314005122/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

On the left, David Bessis (Tinyclues) and on the right, Mireille Messine (Splio) (Photo: Splio)

Splio works with more than 400 brands, including Decathlon, Longchamp and Orange, and has been developing its own Individuation® marketing solution since 2021. Based on machine learning (AI), this solution addresses the dual challenge currently faced within CRM: how to personalize the customer experience for each individual whilst offering marketers a simple solution for large-scale orchestration.

The technological power of the Tinyclues platform increases the value proposition of Splio. A recent winner of both the Sammy and MarTech Breakthrough awards, Tinyclues is currently the most powerful predictive engine on the market, since it is the only one fueled by deep learning. It allows for the automated processing of huge volumes of first-party data for precise customer behaviour prediction. Over 100 brands use Tinyclues on a daily basis, including Veepee, Fnac, Accor, Samsung, Tiffany & Co and SNCF Connect.

The acquisition of Tinyclues thus enables Splio to establish itself as the European leader in AI-powered CRM thanks to its Individuation® marketing software, which can be rapidly and easily deployed across all industries and for companies of all sizes.

AI has become the new standard for better understanding customers and personalizing large-scale marketing communications regardless of industry or business size. Individuation® marketing based on machine learning was an initial response to these challenges. The Tinyclues platform, based on deep learning, strengthens our leadership, and provides new opportunities for sectoral and geographical growth.” Mireille Messine, CEO of Splio.

For a long time, Splio and Tinyclues have shared the same vision of CRM and the same ‘one-to-one at scale’ ambition for clients. Joining Splio enables our deep learning platform to express its full potential by allowing brands to carry out predictive marketing, including customer management and activation.” David Bessis, CEO of Tinyclues.

As a result of this acquisition, Splio now has 250 employees in Europe and the MEA and a portfolio of 500 business clients, from medium-sized companies to large groups from a large range of industries (retail, restaurant, telecoms, travel, hotel, leisure, etc.) with an annual recurring revenue over €30m.

About Splio

Splio is a Martech company headquartered in Paris, with 200 employees, 90 of whom work in Product and R&D, and five offices in Europe and the MEA.

Splio provides a SaaS Individuation® marketing platform to B2C customer marketing professionals. The company has a portfolio of more than 400 brands, from medium-sized enterprises to major groups from four key industries (retail, e-commerce, restaurant and telecom), including Longchamp, Decathlon, Rue du Commerce, Nicolas, Brioche Dorée and Orange.

Splio aims to empower marketing automation with Individuation® enabling companies to activate and engage each of their customers on a case-by-case basis in a unique relationship using AI.

The Individuation® marketing platform is based on a one-of-a-kind innovation that automates each day the most relevant communications to the most appropriate channels for each one of a companies’ customers. The platform is uniquely capable of calculating the optimum based both on a company’s objectives and on the appetencies of each of its customers.

Mireille Messine is the CEO of Splio and Gregory Chapron the Co-CEO. Investors include Sofiouest, Ring Capital, BPI-FAN, Omnes, Seventure, Amundi PEF, BNP Paribas Développement and SWEN.

About Tinyclues

Tinyclues is a Martech company whose precision-AI targets individuals based on buying propensity. Over 100 brands currently use the solution, including Veepee, Fnac, Accor, Samsung, Tiffany & Co and SNCF Connect.

Tinyclues’ cutting-edge technology analyses often-ignored first-party data signals so that CRM teams can accurately predict customer purchase intent and easily orchestrate complex marketing plans.

Tinyclues was the winner of the Sammy Award for Product of the Year in 2021 and the Martech Breakthrough Award for Best CRM Solution for Enterprises in 2021 and 2022. Tinyclues has been listed as a ‘Vendor to Watch’ in Gartner’s Magic Quadrant for Digital Marketing Analytics and as a ‘Cool Vendor’ within its Multichannel Marketing Report. In addition, G2 awarded Tinyclues the ‘Users Love Us’ and ‘High Performer’ certificates in 2021 and 2022.

Tinyclues’ investors include ISAI, Elaia, Alven Capital and EQT Ventures.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230314005122/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Lone Star Announces Sale of SPX FLOW to ITT Inc.5.12.2025 13:30:00 CET | Press release

Lone Star Funds (“Lone Star”) today announced the signing by an affiliate of Lone Star Fund XI, LP of a definitive agreement to sell SPX FLOW, Inc. (“SPX FLOW”), a leading provider of highly engineered equipment and process technologies for attractive end markets including industrial, health and nutrition, to ITT Inc. (NYSE: ITT) for $4.775 billion in cash and shares of common stock. Based in Charlotte, N.C., SPX FLOW focuses on process technologies delivering mixing, blending, fluid handling, separation, thermal heat transfer and other solutions integral to industrial, health and nutrition markets. The company has operations in more than 25 countries and sales in more than 140 countries. In partnership with Lone Star, SPX FLOW has focused on improving its sales execution and operating platform, while ensuring high quality and innovative product development. The management team has improved the company’s commercial organization and executed growth initiatives to build its presence in e

AmTrust Financial Services and Blackstone Credit & Insurance Close Strategic Transaction and Launch Newly Formed Multinational MGACompany Named ANV Group Holdings Ltd.5.12.2025 13:00:00 CET | Press release

Strategic Transaction Unlocks Value for AmTrust and Positions ANV Group Holdings for Accelerated GrowthFormer AmTrust President Adam Karkowsky Leading ANV Group Holdings as Chairman and CEO AmTrust Financial Services, Inc. (“AmTrust” or the “Company”), a global specialty property casualty insurer, and Blackstone Credit & Insurance (“BXCI”), today announced the closing of a strategic transaction under which AmTrust and funds managed by BXCI have partnered to spin-off certain of AmTrust’s Managing General Agencies (“MGAs”) and fee-based businesses in the U.S., United Kingdom, and Continental Europe, into ANV Group Holdings Ltd. (“ANV”), a newly formed independent company, following receipt of regulatory approvals. AmTrust and ANV have entered into a ten-year capacity agreement through which AmTrust will remain the underwriter for the existing books of business offered through the MGAs. As previously announced on September 15, 2025, the agreement includes seven AmTrust subsidiaries: ANV S

Galderma Opens up New Chapter for Sculptra® with MDR Certification and New Expanded Indication for Body5.12.2025 07:00:00 CET | Press release

Sculptra®, the first proven regenerative biostimulator, has received European Union (EU) Medical Device Regulation (MDR) certification, expanding its current clinical application for the face to include gluteal area, posterior thighs, décolletage, and upper arms1 Studies investigating the efficacy of Sculptra on areas beyond the face show patients experienced progressive improvements in skin quality (including the improvement in cellulite appearance), firmness, lift, projection, and contour Sculptra’s versatility and new indication allow practitioners to shift patient treatment goals beyond rejuvenation toward enhancement, meeting evolving patient needs The certification validates Sculptra’s safety performance, efficacy, and quality, reinforcing Galderma’s commitment to innovation and meeting evolving patient needs Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the certification of Sculptra for body indications in the European Union (EU) following its

Northern Escape Heli-Skiing Takes the Title of “World’s Best Heli-Ski-Operator” for the 4th Year Running5.12.2025 02:40:00 CET | Press release

4x World’s Best Heli-Skiing Operation near Terrace, BC Northern Escape Heli-Skiing (NEH) has been named World’s Best Heli-Ski Operator 2025 by the World Ski Awards, marking its fourth straight victory following years 2022, 2023 and 2024. This recognition places NEH amongst an elite group of ski tourism operators consistently voted best in the world by industry leaders and enthusiasts alike. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251204074550/en/ A four-year run built on reliability NEH operates in British Columbia’s Skeena Mountains, where deep northern snow and vast terrain come together with small-group heli-skiing and heli snowboarding. When helicopters can’t safely fly, NEH has cat skiing readily available as a backup — an exceedingly rare offering in this industry. The operation spans over 833,571 wild acres of alpine bowls, glaciers and old-growth tree skiing. The NEH experience Guests choose from three lodge f

IDE034, a Bispecific ADC Licensed by Biocytogen to IDEAYA, Receives FDA IND Clearance5.12.2025 01:00:00 CET | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), announced that its partner IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision oncology company, has received the clearance of an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA) for the initiation of a Phase 1 clinical trial of IDE034, a potential first-in-class B7H3/PTK7 bispecific antibody-drug conjugate (ADC). IDEAYA expects to begin patient enrollment in Q1 2026, initially evaluating patients with solid tumors known to express B7H3 and PTK7, including lung, colorectal, head and neck, and ovarian/gynecological cancers. IDE034 is a bispecific B7H3/PTK7 TOP1 ADC, independently developed by Biocytogen and licensed to IDEAYA in July 2024. The IND clearance marks an important milestone for this licensed program, supporting subsequent clinical development of IDE034, while highlighting Biocytogen’s technical capabilities in bispecific ADC discovery and development. Dr. Yue

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye